However, over the past decade, most functions of NSD2 have been identified in carcinogeneses, such as renal cell carcinoma (Han et al., 2019), colorectal cancer (Chen et al., 2019), osteosarcoma (He et al., 2019), and multiple myeloma (Kuo et al., 2011). Here, NSD2 is linked to plasma cell myeloma.